News & Updates

Placing awake COVID-19 patients with acute hypoxaemic respiratory failure (AHRF) in a prone position is an efficacious intervention in terms of both reducing mortality and preventing intubation, according to an individual participant data meta-analysis.

Antibiotic treatment may be done for 5 days, as opposed to at least 7 days, in hospitalized patients with community-acquired pneumonia (CAP) who had achieved clinical stability by day 3 to 5, suggests a study presented at ESCMID Global 2025.

Updated data from the EPIC-HR* trial show reduced duration of COVID-19 symptoms and utilization of healthcare resources with nirmatrelvir/ritonavir (NMV/r) in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19.